Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Oscine Therapeutics
Deal Watch: Affimed Teams Up In Immuno-Oncology With Roivant, Artiva
German biotech could realize more than $2bn in earnouts under pact with Roivant. Galmed teams with MyBiotics in attempt to optimize clinical response to its Phase III NASH candidate Aramchol.
- Drug Discovery Tools
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Oscine Corp.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.